MDT — Medtronic plc.
Is MDT overbought or oversold? Here is the current MarketMoodz read.
Medtronic plc. (MDT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Devices) last closed at $86.38. The rating moved from Neutral to Oversold on September 24, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$86.38
- Last changeMoved from Neutral to Oversold on September 24, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Medtronic benefits from a diversified device portfolio, strong market positions in multiple therapy areas, and consistent cash generation that supports R&D and shareholder returns. Near-term headwinds include macro-driven elective procedure variability, reimbursement pressures, and supply-chain risks, but a steady pipeline of product introductions, exposure to outpatient and emerging-market growth, and disciplined capital allocation provide a path to recover and reaccelerate revenue. Market sentiment is cautious; outperformance depends on stabilizing procedure volumes, clear regulatory/approval progress, and execution on margin initiatives.
Key factors
- Diversified product portfolio across cardiac, neuro, diabetes, and spinal segments providing resilient revenue streams and reduced single-product dependence
- Leading market share in several core device categories (implantable cardiac devices, insulin pumps, surgical instruments) and deep customer relationships with hospitals and health systems
- Strong free cash flow generation and capital allocation record (dividends, buybacks, selective M&A) supporting shareholder returns and R&D funding
- Ongoing new product launches and incremental pipeline approvals that can drive mid-term revenue growth and margin expansion
- Exposure to emerging markets and outpatient procedural shift provides multi-year secular growth opportunities
- Valuation discounts modestly vs. peers amid near-term macro uncertainty, offering upside if procedure volumes stabilize and supply-chain pressures ease
Risks
- Procedure-volume sensitivity to macro weakness or delayed elective procedures reducing near-term sales
- Reimbursement and policy pressure (Medicare/IRA dynamics and Medicare Advantage plan design changes) that could compress pricing and hospital/device adoption
- Supply-chain disruptions or component shortages that raise costs or delay product shipments
- Regulatory actions, product recalls or safety issues that could harm revenue and reputation
- Intense competition from other large medtech firms and emerging specialized device/therapy entrants
- Prolonged risk-off investor sentiment and IPO/financing windows cooling that can depress valuation multiples for medtech
- Large-scale M&A integration risk or execution missteps on new product commercialization
Latest MarketMoodz coverage
- BTIG Upgrades Medtronic to Buy; Stock Trades at Valuation Discount2026-06-04
- Tempus AI Stock Rises on ALERT Trial Boost for AI EHR2026-04-01
- GlucoTrack stock rises as data backs FDA filing plans for implantable CGM2026-03-27
- Medtronic, Genuine Parts And 3 Stocks To Watch Heading Into Tuesday2026-02-17
- Medtronic Wins FDA Nod for Spine System Aimed at Cutting Repeat Imaging2026-02-13
See today's live rating, score and targets
Members see the live hourly rating for MDT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.